FBN1

protein-coding

fibrillin 1, the group of Fibrillins

Gene summary

This gene encodes a member of the fibrillin family of proteins. The encoded preproprotein is proteolytically processed to generate two proteins including the extracellular matrix component fibrillin-1 and the protein hormone asprosin. Fibrillin-1 is an extracellular matrix glycoprotein that serves as a structural component of calcium-binding microfibrils. These microfibrils provide force-bearing structural support in elastic and nonelastic connective tissue throughout the body. Asprosin, secreted by white adipose tissue, has been shown to regulate glucose homeostasis. Mutations in this gene are associated with Marfan syndrome and the related MASS phenotype, as well as ectopia lentis syndrome, Weill-Marchesani syndrome, Shprintzen-Goldberg syndrome and neonatal progeroid syndrome. [provided by RefSeq, Apr 2016]

Previous symbols:
  • FBN
  • MFS1
  • WMS

MANE transcript

NM_000138.5

Inheritance

AD, AR

ClinVar variants

P:3734U:2531B:1528

Top phenotype

Marfan syndrome; MASS syndrome; Shprintzen-Goldberg syndrome; Marfanoid-progeroid-lipodystrophy syndrome; Ectopia lentis 1, familial; Geleophysic dysplasia 2; Weill-Marchesani syndrome 2

gnomAD constraint

pLI —, LoF o/e 0.02

Max pathogenic AF

—

Genomic locus

chr15:48,408,313-48,645,721

External References & Databases

Transcript & Mutation Effects

hg38 • Region Span ~237.4 kb
Loading mutation effect viewer...

GenCC Phenotypes & Disease Associations

Curated gene-disease validity assertions and inheritance patterns

Shprintzen-Goldberg syndromeLIMITED

Inheritance Pattern: Unknown

Disease ID:MONDO:0008426

Submitter: Labcorp Genetics (formerly Invitae)

Shprintzen-Goldberg syndromeNO_KNOWN

Inheritance Pattern: AD

Disease ID:MONDO:0008426

Submitter: ClinGen

The relationship between *FBN1* and Shprintzen-Goldberg syndrome was first reported in 1996 by Sood et al. (PMID: 8563763). However, the *FBN1* missense variant in this report has been found at a higher than expected frequency in the general population and is therefore not considered evidence in this evaluation. Two additional missense variants (PMIDs: 19293843, 27160103) have been observed at frequencies in the general population too high to be considered as evidence. Three additional variants (PMIDs: 8563763, 16333834, 19293843) were not evaluated as the clinical presentation of the affected individuals was more consistent with Marfan syndrome than Shprintzen-Goldberg syndrome. In 2012, heterozygous pathogenic variants in the gene *SKI* were reported as the genetic cause of Shprintzen-Goldberg syndrome (PMIDs: 23023332, 23103230). In summary, the evidence supporting a relationship between Shprintzen-Goldberg syndrome and *FBN1* is disputed. This classification was approved by the ClinGen Intellectual Disability and Autism Gene Curation Expert Panel on December 1, 2021 (SOP Version 9).

Marfan syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007947

Submitter: G2P

Marfan syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007947

Submitter: Genomics England PanelApp

Acromicric dysplasiaSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007055

Submitter: Orphanet

progeroid and marfanoid aspect-lipodystrophy syndromeMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0014831

Submitter: Ambry Genetics

familial thoracic aortic aneurysm and aortic dissectionDEFINITIVE

Inheritance Pattern: Unknown

Disease ID:MONDO:0019625

Submitter: ClinGen

progeroid and marfanoid aspect-lipodystrophy syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0014831

Submitter: Labcorp Genetics (formerly Invitae)

Weill-Marchesani syndrome 2, dominantSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0012013

Submitter: Labcorp Genetics (formerly Invitae)

geleophysic dysplasiaSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0000127

Submitter: Orphanet

Marfan syndromeDEFINITIVE

Inheritance Pattern: AR

Disease ID:MONDO:0007947

Submitter: G2P

isolated ectopia lentisSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0015998

Submitter: Orphanet

ectopia lentis 1, isolated, autosomal dominantLIMITED

Inheritance Pattern: AD

Disease ID:MONDO:0007514

Submitter: G2P

progeroid and marfanoid aspect-lipodystrophy syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0014831

Submitter: Orphanet

progeroid and marfanoid aspect-lipodystrophy syndromeMODERATE

Inheritance Pattern: AD

Disease ID:MONDO:0014831

Submitter: Ambry Genetics

Marfan syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007947

Submitter: Orphanet

neonatal Marfan syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0017309

Submitter: Orphanet

Marfan syndromeDEFINITIVE

Inheritance Pattern: AD

Disease ID:MONDO:0007947

Submitter: Ambry Genetics

Weill-Marchesani syndrome 2, dominantSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0012013

Submitter: G2P

Weill-Marchesani syndromeSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0018096

Submitter: Orphanet

stiff skin syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0008492

Submitter: Labcorp Genetics (formerly Invitae)

familial thoracic aortic aneurysm and aortic dissectionSUPPORTIVE

Inheritance Pattern: AD

Disease ID:MONDO:0019625

Submitter: Orphanet

Marfan syndromeSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007947

Submitter: Labcorp Genetics (formerly Invitae)

stiff skin syndromeLIMITED

Inheritance Pattern: AD

Disease ID:MONDO:0008492

Submitter: Ambry Genetics

Acromicric dysplasiaSTRONG

Inheritance Pattern: AD

Disease ID:MONDO:0007055

Submitter: Ambry Genetics

Clinical Genomic Database (CGD)

Marfan syndrome; MASS syndrome; Shprintzen-Goldberg syndrome; Marfanoid-progeroid-lipodystrophy syndrome; Ectopia lentis 1, familial; Geleophysic dysplasia 2; Weill-Marchesani syndrome 2AD

Manifestation: Cardiovascular; Craniofacial; Dental; Dermatologic; Musculoskeletal; Neurologic; Ophthalmologic; Pulmonary

Intervention: Cardiovascular; Musculoskeletal; Ophthalmologic; Pharmacogenomic; Pulmonary

Rationale: Medications that reduce aortic wall hemodynamic stress (eg, beta blockers) have been shown to be effective; Afterload-reducing agents can improve cardiovascular function in CHF; Surgical aortic repair is indicated depending on parameters such as size and rate of change of aorta; Other issues also require attention and may benefit from regular surveillance, such as those involving ophthalomologic, pulmonary, and skeletal complications; Certain agents and circumstances should be avoided, including activities that impose cardiovascular or musculoskeletal risk, as well as agents such as decongestants, caffeine; LASIK is typically contraindicated; Geleophysic dysplasia may frequently be clinically recognizable, but individuals can have cardiovascular manifestations such as progressive cardiac valve thickening necessitating surgical interventions very early in childhood, and early diagnosis may be beneficial to allow early treatment; In Weill-Marchesani syndrome, awareness of the risk of certain ophthalmological complications (including glaucoma) can allow prompt awareness and treatment

Refs: 1157278; 370588; 6182156; 2938007; 3189335; 2322060; 1852208; 2337033; 1864149; 1301946; 1569206; 1736263; 1542340; 8406497; 7802039; 7573130; 8152445; 8863159; 8733052; 8790089; 8563763; 9150726; 9761390; 10489951; 10219065; 11256662; 11700157; 12446365; 11845856; 11826022; 12525539; 14598350; 15054843; 15731757; 15517394; 16596670; 16202954; 17366579; 18579813; 19996017; 19353630; 20375004; 20301510; 20301776; 20886638; 20979188; 21063442; 21594992; 21594993; 21683322; 21883168; 21932315; 22034023; 22461464; 22736615; 22876116; 22950452; 24613577Source: CGD (NHGRI)

ClinVar Associated Diseases & Phenotypes

Reported disease conditions connected to FBN1 variants in ClinVar

108 Conditions Cataloged
Marfan syndromeTotal: 6996
Familial thoracic aortic aneurysm and aortic dissectionTotal: 6811
not providedTotal: 2130
not specifiedTotal: 857
Acromicric dysplasiaTotal: 440
Stiff skin syndromeTotal: 432
Ectopia lentis 1, isolated, autosomal dominantTotal: 431
Progeroid and marfanoid aspect-lipodystrophy syndromeTotal: 345

ClinVar Variants & Pathogenicity by Type

Statistics based on transcript NM_000138.5. Only rare variants are included.

We include only reliable ClinVar variants with their consequences to MANE Select, MANE Plus Clinical transcripts, or transcripts with TSL equal to 1. Click a count to filter the variants table below.

Slight differences between displayed counts and ClinVar may occur due to a different transcript/consequence chosen by our variant effect predictor, or because we classify Benign/Likely benign as Likely benign and Pathogenic/Likely pathogenic as Likely pathogenic.

EffectPLPVUSLBBSum
synonymous
4
clinvar
9
clinvar
44
clinvar
1212
clinvar
28
clinvar
1297
missense
556
clinvar
1188
clinvar
2458
clinvar
263
clinvar
25
clinvar
4490
nonsense
394
clinvar
101
clinvar
5
clinvar
500
start loss
6
clinvar
2
clinvar
8
frameshift
846
clinvar
243
clinvar
11
clinvar
1100
splice donor/acceptor (+/-2bp)
188
clinvar
197
clinvar
13
clinvar
398
Total1994174025311475537793

Highest pathogenic variant AF is 0.00008426479

Loading ClinVar variants...

Transcript Catalog

Annotated transcript isoforms across RefSeq and Ensembl databases

Showing 4 of 12 transcripts
Transcript IDSourceProtein IDCoding ExonsMANE Status
NM_000138.5RefSeqNP_000129.365MANE Select
ENST00000316623.10EnsemblENSP00000325527.565MANE Select
NM_001406716.1RefSeqNP_001393645.165Standard
NM_001406717.1RefSeqNP_001393646.18Standard

Gene Ontology (GO) Annotations & Pathways

Biological processes, molecular functions, cellular components and pathways

Pathways ConsensusPathDB

  • Hypothesized Pathways in Pathogenesis of Cardiovascular Disease
  • Post-translational protein phosphorylation
  • Integrin cell surface interactions
  • Post-translational protein modification
  • Metabolism of proteins

Biological Process

  • skeletal system development
  • metanephros development
  • heart development
  • regulation of signaling receptor activity
  • extracellular matrix organization

Molecular Function

  • integrin binding
  • hormone activity
  • extracellular matrix structural constituent
  • calcium ion binding
  • protein binding

Cellular Component

  • microfibril
  • extracellular region
  • basement membrane
  • extracellular space
  • endoplasmic reticulum lumen

gnomAD Constraint

Source: gnomAD

Gene type
protein_coding
Transcript type
protein_coding
Transcript
ENST00000316623
Coding exons
65
Length
237544
Individuals with no LoFs
125733
Homozygous LoFs
0
Heterozygous LoFs
14
Defined
125747
p
0.0000557
Z-ScoreObservedExpectedObserved/ExpectedMutation RateTotal Possible
Missense5.0610381.61e+30.6450.000093219158
Missense (PolyPhen)346757.540.456748847
Synonymous0.2215735800.9880.00003655163
Loss of Function11.531590.01890.000008941983

Population LoF Frequency

PopulationCAFp-valueStatus
African00.0absent
Latino/Admixed American00.0absent
Ashkenazi Jewish00.0absent
East Asian00.0absent
Finnish0.000420.00042rare
European (Non-Finnish)0.00000880.0000088rare
South Asian0.000130.000065rare
Other0.000330.00033rare

dbNSFP Gene Annotations

Source: dbNSFP

Function
FUNCTION: Fibrillin-1: Structural component of the 10-12 nm diameter microfibrils of the extracellular matrix, which conveys both structural and regulatory properties to load-bearing connective tissues (PubMed:1860873, PubMed:15062093). Fibrillin-1- containing microfibrils provide long-term force bearing structural support. In tissues such as the lung, blood vessels and skin, microfibrils form the periphery of the elastic fiber, acting as a scaffold for the deposition of elastin. In addition, microfibrils can occur as elastin-independent networks in tissues such as the ciliary zonule, tendon, cornea and glomerulus where they provide tensile strength and have anchoring roles. Fibrillin-1 also plays a key role in tissue homeostasis through specific interactions with growth factors, such as the bone morphogenetic proteins (BMPs), growth and differentiation factors (GDFs) and latent transforming growth factor-beta-binding proteins (LTBPs), cell- surface integrins and other extracellular matrix protein and proteoglycan components (PubMed:27026396). Regulates osteoblast maturation by controlling TGF-beta bioavailability and calibrating TGF-beta and BMP levels, respectively (By similarity). Negatively regulates osteoclastogenesis by binding and sequestering an osteoclast differentiation and activation factor TNFSF11. This leads to disruption of TNFSF11-induced Ca(2+) signaling and impairment of TNFSF11-mediated nuclear translocation and activation of transcription factor NFATC1 which regulates genes important for osteoclast differentiation and function (PubMed:24039232). Mediates cell adhesion via its binding to cell surface receptors integrins ITGAV:ITGB3 and ITGA5:ITGB1 (PubMed:12807887, PubMed:17158881). Binds heparin and this interaction has an important role in the assembly of microfibrils (PubMed:11461921). {ECO:0000250|UniProtKB:Q61554, ECO:0000269|PubMed:11461921, ECO:0000269|PubMed:12807887, ECO:0000269|PubMed:15062093, ECO:0000269|PubMed:17158881, ECO:0000269|PubMed:1860873, ECO:0000269|PubMed:24039232, ECO:0000303|PubMed:27026396}.;
Disease
DISEASE: Marfan syndrome (MFS) [MIM:154700]: A hereditary disorder of connective tissue that affects the skeletal, ocular, and cardiovascular systems. A wide variety of skeletal abnormalities occurs with Marfan syndrome, including scoliosis, chest wall deformity, tall stature, abnormal joint mobility. Ectopia lentis occurs in most of the patients and is almost always bilateral. The leading cause of premature death is progressive dilation of the aortic root and ascending aorta, causing aortic incompetence and dissection. Neonatal Marfan syndrome is the most severe form resulting in death from cardiorespiratory failure in the first few years of life. {ECO:0000269|PubMed:10425041, ECO:0000269|PubMed:10441597, ECO:0000269|PubMed:10694921, ECO:0000269|PubMed:11700157, ECO:0000269|PubMed:11826022, ECO:0000269|PubMed:12161601, ECO:0000269|PubMed:12203992, ECO:0000269|PubMed:12402346, ECO:0000269|PubMed:1301946, ECO:0000269|PubMed:14695540, ECO:0000269|PubMed:15161917, ECO:0000269|PubMed:15221638, ECO:0000269|PubMed:1569206, ECO:0000269|PubMed:16220557, ECO:0000269|PubMed:16222657, ECO:0000269|PubMed:17657824, ECO:0000269|PubMed:18435798, ECO:0000269|PubMed:1852208, ECO:0000269|PubMed:19533785, ECO:0000269|PubMed:19941982, ECO:0000269|PubMed:20803651, ECO:0000269|PubMed:21542060, ECO:0000269|PubMed:22772377, ECO:0000269|PubMed:7611299, ECO:0000269|PubMed:7738200, ECO:0000269|PubMed:7762551, ECO:0000269|PubMed:7870075, ECO:0000269|PubMed:7951214, ECO:0000269|PubMed:7977366, ECO:0000269|PubMed:8004112, ECO:0000269|PubMed:8040326, ECO:0000269|PubMed:8071963, ECO:0000269|PubMed:8136837, ECO:0000269|PubMed:8281141, ECO:0000269|PubMed:8406497, ECO:0000269|PubMed:8504310, ECO:0000269|PubMed:8863159, ECO:0000269|PubMed:8882780, ECO:0000269|PubMed:9016526, ECO:0000269|PubMed:9254848, ECO:0000269|PubMed:9338581, ECO:0000269|PubMed:9401003, ECO:0000269|PubMed:9452085, ECO:0000269|PubMed:9837823, ECO:0000269|Ref.68}. Note=The disease is caused by mutations affecting the gene represented in this entry. The majority of the more than thousand mutations in FBN1 currently known are point mutations, the rest are frameshifts and splice site mutations. Marfan syndrome has been suggested in at least 2 historical figures, Abraham Lincoln and Paganini.; DISEASE: Ectopia lentis 1, isolated, autosomal dominant (ECTOL1) [MIM:129600]: An ocular abnormality characterized by partial or complete displacement of the lens from its space resulting from defective zonule formation. {ECO:0000269|PubMed:11700157, ECO:0000269|PubMed:11826022, ECO:0000269|PubMed:12203992, ECO:0000269|PubMed:17657824, ECO:0000269|PubMed:8188302}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Weill-Marchesani syndrome 2 (WMS2) [MIM:608328]: A rare connective tissue disorder characterized by short stature, brachydactyly, joint stiffness, and eye abnormalities including microspherophakia, ectopia lentis, severe myopia and glaucoma. {ECO:0000269|PubMed:12525539}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Overlap connective tissue disease (OCTD) [MIM:604308]: Heritable disorder of connective tissue characterized by involvement of the mitral valve, aorta, skeleton, and skin. MASS syndrome is closely resembling both the Marfan syndrome and the Barlow syndrome. However, no dislocation of the lenses or aneurysmal changes occur in the aorta, and the mitral valve prolapse is by no means invariable. {ECO:0000269|PubMed:2739055}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Stiff skin syndrome (SSKS) [MIM:184900]: A syndrome characterized by hard, thick skin, usually over the entire body, which limits joint mobility and causes flexion contractures. Other occasional findings include lipodystrophy and muscle weakness. {ECO:0000269|PubMed:20375004}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Geleophysic dysplasia 2 (GPHYSD2) [MIM:614185]: An autosomal dominant disorder characterized by severe short stature, short hands and feet, joint limitations, and skin thickening. Radiologic features include delayed bone age, cone-shaped epiphyses, shortened long tubular bones, and ovoid vertebral bodies. Affected individuals have characteristic facial features including a 'happy' face with full cheeks, shortened nose, hypertelorism, long and flat philtrum, and thin upper lip. Other distinctive features include progressive cardiac valvular thickening often leading to an early death, toe walking, tracheal stenosis, respiratory insufficiency, and lysosomal-like storage vacuoles in various tissues. {ECO:0000269|PubMed:21683322}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Acromicric dysplasia (ACMICD) [MIM:102370]: An autosomal dominant disorder characterized by severe short stature, short hands and feet, joint limitations, and skin thickening. Radiologic features include delayed bone age, cone-shaped epiphyses, shortened long tubular bones, and ovoid vertebral bodies. Affected individuals have distinct facial features, including round face, well-defined eyebrows, long eyelashes, bulbous nose with anteverted nostrils, long and prominent philtrum, and thick lips with a small mouth. Other characteristic features include hoarse voice and pseudomuscular build, and there are distinct skeletal features as well, including an internal notch of the femoral head, internal notch of the second metacarpal, and external notch of the fifth metacarpal. {ECO:0000269|PubMed:21683322}. Note=The disease is caused by mutations affecting the gene represented in this entry.; DISEASE: Marfan lipodystrophy syndrome (MFLS) [MIM:616914]: A syndrome characterized by congenital lipodystrophy, a progeroid facial appearance due to lack of subcutaneous fat, and variable signs of Marfan syndrome. Clinical features include premature birth with an accelerated linear growth disproportionate to the weight gain, ectopia lentis, aortic dilatation, dural ectasia, and arachnodactyly. Mental and motor development are within normal limits. {ECO:0000269|PubMed:20979188, ECO:0000269|PubMed:21594992, ECO:0000269|PubMed:21594993, ECO:0000269|PubMed:24039054, ECO:0000269|PubMed:24613577, ECO:0000269|PubMed:24665001, ECO:0000269|PubMed:26860060, ECO:0000269|PubMed:27087445}. Note=The disease is caused by mutations affecting the gene represented in this entry. Asprosin: Mutations specifically affect Asprosin, a hormone peptide present at the C-terminus of Fibrillin-1 chain, which is cleaved from Fibrillin-1 following secretion (PubMed:27087445). {ECO:0000269|PubMed:27087445}.;

Recessive Scores

pRec
0.114

Intolerance Scores

LoFtool
0.00289
RVIS EVS
-2.81
RVIS percentile EVS
0.64

Essentials

Essential (CRISPR)
N
Essential (CRISPR2)
N
Essential (gene trap)
N
Indispensability pred.
E
Indispensability score
0.748

Gene Damage Prediction

AllRecessiveDominant
MendelianMediumMediumMedium
Primary ImmunodeficiencyMediumMediumMedium
CancerMediumMediumMedium
For research and educational, non-commercial use only. Not for clinical or diagnostic use. GeneBe does not provide medical advice. Data use for AI modeling is prohibited: if used, the cost is $0.001 per byte of downloaded uncompressed data.